> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Thermo Fisher Gets 2 EUAs for Covid Tests
- URL: https://www.fdaweb.com/thermo-fisher-gets-2-euas-for-covid-tests/
- Published: 2021-08-16T12:00:00.000Z
- Updated: 2026-09-14T17:10:41.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5149943

FDA has granted Thermo Fisher Scientific emergency use authorizations for the TaqPath Covid-19 Fast PCR Combo Kit 2.0 and the TaqPath Covid-19 RNase P Combo Kit 2.0, assays designed with increased target redundancy to compensate for current mutations and emerging SARS-CoV-2 variants. “Both PCR-based kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19,” the company says. “This built-in redundancy helps ensure accuracy of results in situations where gene expression in the virus vary as new mutations emerge.”  

Thermo Fisher says the TaqPath Fast PCR Combo Kit 2.0 assesses raw saliva and uses a simple workflow from sample collection direct to PCR to help preserve supplies. Results are returned in about two hours. The TaqPath RNase P Combo Kit 2.0 is designed with an approximate three-hour turnaround time and can detect SARS-CoV-2 from individuals suspected of Covid-19 as well as from patients who are asymptomatic.